<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367050">
  <stage>Registered</stage>
  <submitdate>5/09/2014</submitdate>
  <approvaldate>15/09/2014</approvaldate>
  <actrnumber>ACTRN12614000988651</actrnumber>
  <trial_identification>
    <studytitle>Should we treat iron deficiency anaemia of pregnancy with lactoferrin? A randomised controlled trial
Lactoferrin Evaluation in Anaemia in Pregnancy</studytitle>
    <scientifictitle>Should we treat iron deficiency anaemia of pregnancy with lactoferrin? A randomised controlled trial
</scientifictitle>
    <utrn>U1111-1161-3807</utrn>
    <trialacronym>LEAP-1</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Iron Deficient Anaemia in Pregnancy</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bovine Lactoferrin 200 mg capsules once a day

Duration of treatment: from enrolment (after 12 weeks gestation) until delivery;
Adherence monitored via treatment diaries and drug accountability logs</interventions>
    <comparator>Iron Sulphate 80 mg capsules once  a day

Duration of treatment: from enrolment (after 12 weeks gestation) until delivery;

Adherence monitored via treatment diaries and drug accountability logs</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Birth Weight</outcome>
      <timepoint>At birth</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Whether oral bLF therapy reduces the proportion of women with IDAP who
receive intravenous iron infusion according to standard protocol OR who do not
respond to treatment and remain anaemic at any time between 34 weeks
gestation and delivery.</outcome>
      <timepoint>Any time to delivery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>proportion &lt;10th centile for birth weight 
</outcome>
      <timepoint>at birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion born &lt;37 weeks gestation</outcome>
      <timepoint>at birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion with birth weight &lt;2500 g</outcome>
      <timepoint>at birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>maternal Hb between 110-130 g/L with normal iron saturation and serum ferritin assessed via blood tests


</outcome>
      <timepoint>at birth </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>maternal haemoconcentration (Hb &gt;130 g/L) assessed via blood tests</outcome>
      <timepoint>at birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>duration of pregnancy</outcome>
      <timepoint>at birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in health related quality of life (HRQoL) using SF12v2 and AQoL8D</outcome>
      <timepoint>baseline, 30days and 6 weeks after birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neonatal iron status. This will be assessed using cord blood sample taken at birth.</outcome>
      <timepoint>At birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in maternal Intraleukin 6 [IL-6] concentration between trial entry and 30 days later. This will be assessed using spare blood from the iron studies.</outcome>
      <timepoint>30 days after treatment start</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of breastfeeding</outcome>
      <timepoint>12months after birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability and maternal adverse effects. Midwifery staff will ask mother tolerability questions such as nausea, constipation etc, monthly until end of treatment. Questions will be in person at routine antenatal visits or over the phone,</outcome>
      <timepoint>To treatment end</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in maternal Hb concentration. Hb levels will be assessed using blood samples</outcome>
      <timepoint>From trial entry to 30 days later and closest to delivery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pregnant women with mild/moderate IDAP [Hb 70 -110 g/L] and gestation &lt;30 weeks and &gt;12 weeks 
OR
Pregnant women likely to develop IDAP [Hb 111-115 g/L and serum ferritin &lt;20micrograms/L ]  and gestation &lt;30 weeks and &gt;12 weeks </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Contraindications to bLF or FeSO4
2. Severe anaemia needing intravenous iron according to local protocol (Hb &lt;70 g/L)
3. Prior treatment with intravenous iron within 30 days
4. Any allergy to milk proteins or to iron products</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>5/01/2015</anticipatedstartdate>
    <actualstartdate>25/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>800</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,NT,QLD,SA,TAS,WA,VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>Locked Bag 77
Camperdown
NSW 1450</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Iron deficiency - the worlds commonest nutritional disorder affects over 2 billion
people (WHO 2008), with women and children at greatest risk. This study aims to evaluate, in a randomised controlled trial (RCT), oral bovine lactoferrin (bLF) vs iron sulphate (FeSO4) in iron deficiency anaemia in pregnancy (IDAP). This study will comparerandomised groups on the following co-primary endpoints: 
1) Fetal growth (birth weight for gestational age)
2) Whether oral bLF therapy reduces the proportion of women with IDAP who receive intravenous iron infusion according to standard protocol OR who do not respond to treatment and remain anaemic at any time between 34 weeks gestation and delivery.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 1 New Lambton NSW 2305</ethicaddress>
      <ethicapprovaldate>22/09/2014</ethicapprovaldate>
      <hrec>HREC/14/HNE/294</hrec>
      <ethicsubmitdate>29/08/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee Tasmania Network</ethicname>
      <ethicaddress>University of Tasmania
Private Bag 1
Hobart Tasmania 7001</ethicaddress>
      <ethicapprovaldate>21/01/2015</ethicapprovaldate>
      <hrec>H0014593</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>William Tarnow-Mordi</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown, NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>leap@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>William Tarnow-Mordi</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown, NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>leap@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>William Tarnow-Mordi</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown, NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>leap@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alpana Ghadge</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown, NSW 1450</address>
      <phone />
      <fax />
      <email>leap@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>